Your browser doesn't support javascript.
New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease.
Ter Arkh ; 91(3): 76-85, 2019 Mar 30.
Artigo em Inglês | MEDLINE | ID: mdl-31094464
Currently, combinations of long-acting beta2-agonists and long-acting anticholinergics are considered as the basic therapy for majority of patients with chronic obstructive pulmonary disease (COPD). These combinations have different pharmacological characteristics and delivery devices that provides different clinical effects and new opportunities for personalized treatment of COPD. Aclidinium/formoterol fixed combination differs from other dual bronchodilators by twice-daily dosing regimen, good safety profile and a specific delivery system. Recent information on clinical efficacy and safety of aclidinium/formoterol combination in COPD patients is given in this article.





Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Tropanos / Broncodilatadores / Antagonistas Muscarínicos / Doença Pulmonar Obstrutiva Crônica / Agonistas de Receptores Adrenérgicos beta 2 / Fumarato de Formoterol / Pulmão Aspecto clínico: Terapia Limite: Humanos Idioma: Inglês Revista: Ter Arkh Ano de publicação: 2019 Tipo de documento: Artigo País de afiliação: Federação Russa